Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART

NCT00296972 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00296972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00296972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2005
Completion date
April 30, 2007
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c, hiv infections